» Articles » PMID: 38198982

Big is Not Better: Comparing Two Alpha-Gal-bearing Glycotopes in Neoglycoproteins As Biomarkers for Leishmania (Viannia) Braziliensis Infection

Overview
Journal Carbohydr Res
Publisher Elsevier
Date 2024 Jan 10
PMID 38198982
Authors
Affiliations
Soon will be listed here.
Abstract

The protozoan parasite Leishmania (Viannia) braziliensis is among Latin America's most widespread Leishmania species and is responsible for tegumentary leishmaniasis (TL). This disease has multiple clinical presentations, with cutaneous leishmaniasis (CL) being the most frequent. It manifests as one or a few localized skin ulcers, which can spread to other body areas. Hence, early diagnosis and treatment, typically with pentavalent antimonials, is critical. Traditional diagnostic methods, like parasite culture, microscopy, or the polymerase chain reaction (PCR) for detection of the parasite DNA, have limitations due to the uneven distribution of parasites in biopsy samples. Nonetheless, studies have revealed high levels of parasite-specific anti-α-Gal antibodies in L. (V.) braziliensis-infected patients. Previously, we demonstrated that the neoglycoprotein NGP28b, consisting of the L. (Leishmania) major type-2 glycoinositolphospholipid (GIPL)-3-derived trisaccharide Galpα1,6Galpα1,3Galfβ conjugated to bovine serum albumin (BSA) via a linker, acts as a reliable serological biomarker (BMK) for L. (V.) braziliensis infection in Brazil. This indicates the presence of GIPL-3 or a similar structure in this parasite, and its terminal trisaccharide either functions as or is part of an immunodominant glycotope. Here, we explored whether extending the trisaccharide with a mannose unit would enhance its efficacy as a biomarker for the serological detection of L. (V.) braziliensis. We synthesized the tetrasaccharide Galpα1,6Galpα1,3Galfβ1,3Manpα(CH)SH (G31) and conjugated it to maleimide-functionalized BSA to afford NGP31b. When we assessed the efficacy of NGP28b and NGP31b by chemiluminescent enzyme-linked immunosorbent assay on a cohort of CL patients with L. (V.) braziliensis infection from Bolivia and Argentina against a healthy control group, both NGPs exhibited similar or identical sensitivity, specificity, and accuracy. This finding implies that the mannose moiety at the reducing end is not part of the glycotope recognized by the parasite-specific anti-α-Gal antibodies in patients' sera, nor does it exert a relevant influence on the terminal trisaccharide's conformation. Moreover, the mannose does not seem to inhibit glycan-antibody interactions. Therefore, NGP31b is a viable and dependable BMK for the serodiagnosis of CL caused by L. (V.) braziliensis.

References
1.
Power M, Fell G, Wright M . Principles for high-quality, high-value testing. Evid Based Med. 2012; 18(1):5-10. PMC: 3585491. DOI: 10.1136/eb-2012-100645. View

2.
Goto H, Lindoso J . Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther. 2010; 8(4):419-33. DOI: 10.1586/eri.10.19. View

3.
Almeida I, Ferguson M, Schenkman S, Travassos L . Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem J. 1994; 304 ( Pt 3):793-802. PMC: 1137404. DOI: 10.1042/bj3040793. View

4.
Viana S, Montoya A, Carvalho A, de Mendonca B, Portillo S, Olivas J . Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins. Emerg Microbes Infect. 2022; 11(1):2147-2159. PMC: 9518598. DOI: 10.1080/22221751.2022.2114852. View

5.
Gazzinelli R, Pereira M, Romanha A, Gazzinelli G, Brener Z . Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunol. 1991; 13(4):345-56. DOI: 10.1111/j.1365-3024.1991.tb00288.x. View